Aardvark Therapeutics, Inc. Common Stock (AARD)
Automate Your Wheel Strategy on AARD
With Tiblio's Option Bot, you can configure your own wheel strategy including AARD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AARD
- Rev/Share 0.0
- Book/Share 6.3127
- PB 1.6538
- Debt/Equity 0.0047
- CurrentRatio 14.0415
- ROIC -0.297
- MktCap 226530106.0
- FreeCF/Share -1.5222
- PFCF -6.8612
- PE -6.1806
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.7846
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AARD | BTIG Research | -- | Buy | -- | $26 | Nov. 7, 2025 |
| Initiation | AARD | Stifel | -- | Buy | -- | $24 | Sept. 29, 2025 |
| Initiation | AARD | H.C. Wainwright | -- | Buy | -- | $40 | June 30, 2025 |
| Initiation | AARD | BofA Securities | -- | Buy | -- | $22 | March 10, 2025 |
| Initiation | AARD | Morgan Stanley | -- | Overweight | -- | $29 | March 10, 2025 |
| Initiation | AARD | RBC Capital Mkts | -- | Outperform | -- | $21 | March 10, 2025 |
| Initiation | AARD | Cantor Fitzgerald | -- | Overweight | -- | $50 | March 10, 2025 |
News
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape Preclinical and clinical data demonstrates the potential of ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after the discontinuation of GLP-1RA Aardvark to host investor webinar on November 5th, 2025 to review ARD-101 and ARD-201 programs, as well as ObesityWeek presentations SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to …
Read More
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
About Aardvark Therapeutics, Inc. Common Stock (AARD)
- IPO Date 2025-02-13
- Website https://aardvarktherapeutics.com
- Industry Biotechnology
- CEO Tien-Li Lee
- Employees 22